Mnemonic Similarity Task to study episodic memory in Parkinson's disease.

Clin Park Relat Disord

Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.

Published: June 2020

Introduction: Parkinson's disease (PD) patients commonly experience episodic memory impairments, which are associated with an increased risk of dementia. The Mnemonic Similarity Task (MST) is a well-validated test to investigate episodic memory changes in healthy aging and in neurodegenerative diseases but has not been studied in PD patients.

Methods: In the MST task, participants respond during a testing phase whether visualized images are "repeat", "similar", or "new", compared to images previously shown during an encoding phase. We tested 17 PD without cognitive impairment (level-II criteria), both off (PD-OFF) and on (PD-ON) dopaminergic medications; and compared PD-OFF with 17 age- and education-matched healthy controls (HC).

Results: We found no influence of dopaminergic medications nor of disease on MST reaction time for any responses ("repeat", "similar", and "new") during the test phase. However, response probabilities showed that the MST is sensitive to subtle PD-related memory impairments. Specifically, PD-OFF responded more frequently with 'repeat', instead of 'similar' during lure trials, compared to HC ( = 0.030). This finding was still significant after correcting for response bias using the Recognition Index ( = 0.005).

Conclusions: PD patients perform the MST without interference from bradykinesia or other PD-related motor symptoms. Our findings suggest that PD patients who do not meet criteria for mild cognitive impairment can have subtle recall or recognition impairments, which can be identified using the MST. We propose the MST as a well-tolerated and sensitive cognitive task in future studies of episodic memory impairment and progressive memory dysfunction in people with PD.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298797PMC
http://dx.doi.org/10.1016/j.prdoa.2020.100062DOI Listing

Publication Analysis

Top Keywords

episodic memory
16
mnemonic similarity
8
similarity task
8
parkinson's disease
8
memory impairments
8
"repeat" "similar"
8
"similar" "new"
8
cognitive impairment
8
dopaminergic medications
8
mst
7

Similar Publications

Background: Population aging and the increase in memory-related diseases have motivated the search for accessible cognitive screening instruments. To develop a digital memory and learning test (DMLT) based on Rey's Auditory Verbal Learning Test (RAVLT) principles to assess cognition in the elderly and identify early cognitive decline.

Methods: The research was divided into two phases: developing the digital test and the experimental phase of comparison with a reference test.

View Article and Find Full Text PDF

Koopman learning with episodic memory.

Chaos

January 2025

AIMdyn, Inc., Santa Barbara, California 93101, USA.

Koopman operator theory has found significant success in learning models of complex, real-world dynamical systems, enabling prediction and control. The greater interpretability and lower computational costs of these models, compared to traditional machine learning methodologies, make Koopman learning an especially appealing approach. Despite this, little work has been performed on endowing Koopman learning with the ability to leverage its own failures.

View Article and Find Full Text PDF

Background: MicroRNAs have been linked to dementia. However, understanding their relation to cognition in the general population is required to determine their potential use for the detection and prevention of age-associated cognitive decline and preclinical dementia. Therefore, we examined the association of circulating microRNAs with cognitive performance in a population-based cohort and the possible underlying mechanisms.

View Article and Find Full Text PDF

Background: The recent approval of two anti-amyloid antibodies, Aducanamab and Lecanamab, have set the stage for the next generation of anti-amyloid treatments. Despite the capability of these treatments to lower Aβ brain levels, there is thus far limited clinical efficacy on cognitive outcomes. Because eligibility for treatment includes individuals with MCI or mild dementia, that often harbor mixed pathologies, the cognitive impact of other brain pathologies may be important.

View Article and Find Full Text PDF

Background: Alzheimer's disease (AD) is sometimes characterized as "type 3 diabetes" because hyperglycemia impairs cognitive function, particularly in the medial temporal lobe (MTL) and prefrontal regions. Further, both AD and type 2 diabetes (T2D) disproportionately impact African Americans. Although people with T2D are generally suggested to have lower episodic memory and executive function, limited data exist in older African Americans.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!